A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
NCT03563014 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164
Last updated 2020-05-20
Summary
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.
Conditions
- Prostatic Neoplasms, Castration-Resistant
Interventions
- DRUG
-
Radium-223 (Xofigo, Bay88-8223)
Follow the physician's prescription in routine clinical practice.
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-31
- Primary Completion
- 2019-01-31
- Completion
- 2019-01-31
Countries
- Belgium
More Related Trials
-
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
NCT04281147 ·Status: COMPLETED
-
A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
NCT04587427 ·Status: COMPLETED
-
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
NCT03223597 ·Status: COMPLETED
-
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
NCT02803437 ·Status: COMPLETED
-
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
NCT00459654 ·Status: COMPLETED ·Phase: PHASE2
-
Radium 223 Following Intermittent ADT
NCT02656563 ·Status: WITHDRAWN ·Phase: PHASE2
-
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
NCT02899104 ·Status: COMPLETED
-
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
NCT04681144 ·Status: COMPLETED
-
Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223
NCT04995614 ·Status: COMPLETED
-
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
NCT01516762 ·Status: NO_LONGER_AVAILABLE
-
Multi-academic Center Study of Xofigo Patients
NCT03419442 ·Status: COMPLETED
-
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
NCT02023697 ·Status: COMPLETED ·Phase: PHASE2
-
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
NCT02398526 ·Status: COMPLETED
-
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
NCT03896984 ·Status: COMPLETED
-
PK in Pts With HRPC & Skeletal Metastes
NCT00667537 ·Status: COMPLETED ·Phase: PHASE1
-
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
NCT03230734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
NCT02518698 ·Status: COMPLETED
-
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
NCT01565746 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
NCT04521361 ·Status: COMPLETED ·Phase: PHASE1
-
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
NCT03325127 ·Status: WITHDRAWN
-
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
NCT02034552 ·Status: COMPLETED ·Phase: PHASE2
-
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
NCT02346526 ·Status: COMPLETED ·Phase: PHASE2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT04704505 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
NCT04232761 ·Status: COMPLETED
-
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
NCT04256993 ·Status: COMPLETED